Given the billion dollar potential of Gilead Sciences Inc.’s sofosbuvir, it’s not particularly surprising that other companies would try to get a piece of the drug’s sales, claiming their patents covered the hepatitis C (HCV) drug. Read More
In the new health care ecosystem where, among other things, drug developers now need to show real-world value, companion diagnostics are evolving as essential components in order for new innovative drugs to prove their worth. This is because they enable these therapies to be targeted to patients who will benefit the most. Read More
